<bill session="117" type="h" number="7667" updated="2023-12-05T10:26:21Z">
  <state datetime="2022-06-08T20:31:13-04:00">PASS_OVER:HOUSE</state>
  <status>
    <unknown datetime="2022-06-08T20:31:13-04:00"/>
  </status>
  <introduced datetime="2022-05-06"/>
  <titles>
    <title type="display">Food and Drug Amendments of 2022</title>
    <title type="short" as="introduced">Food and Drug Amendments of 2022</title>
    <title type="short" as="introduced" partial="1">Biosimilar User Fee Amendments of 2022</title>
    <title type="short" as="introduced" partial="1">Generic Drug User Fee Amendments of 2022</title>
    <title type="short" as="introduced" partial="1">Medical Device User Fee Amendments of 2022</title>
    <title type="short" as="introduced" partial="1">Prescription Drug User Fee Amendments of 2022</title>
    <title type="short" as="reported to house">Food and Drug Amendments of 2022</title>
    <title type="short" as="reported to house" partial="1">Biosimilar User Fee Amendments of 2022</title>
    <title type="short" as="reported to house" partial="1">Generic Drug User Fee Amendments of 2022</title>
    <title type="short" as="reported to house" partial="1">Medical Device User Fee Amendments of 2022</title>
    <title type="short" as="reported to house" partial="1">Prescription Drug User Fee Amendments of 2022</title>
    <title type="short" as="passed house">Food and Drug Amendments of 2022</title>
    <title type="short" as="passed house" partial="1">Biosimilar User Fee Amendments of 2022</title>
    <title type="short" as="passed house" partial="1">Generic Drug User Fee Amendments of 2022</title>
    <title type="short" as="passed house" partial="1">Medical Device User Fee Amendments of 2022</title>
    <title type="short" as="passed house" partial="1">Prescription Drug User Fee Amendments of 2022</title>
    <title type="official" as="introduced">To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes.</title>
  </titles>
  <sponsor bioguide_id="E000215"/>
  <cosponsors>
    <cosponsor bioguide_id="G000558" joined="2022-05-06"/>
    <cosponsor bioguide_id="M001159" joined="2022-05-06"/>
    <cosponsor bioguide_id="P000034" joined="2022-05-06"/>
  </cosponsors>
  <actions>
    <action datetime="2022-05-06">
      <text>Introduced in House</text>
    </action>
    <action datetime="2022-05-06" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2022-05-09">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
    <action datetime="2022-05-11">
      <text>Subcommittee Consideration and Mark-up Session Held.</text>
    </action>
    <action datetime="2022-05-11">
      <text>Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 30 - 0 .</text>
    </action>
    <action datetime="2022-05-18">
      <text>Committee Consideration and Mark-up Session Held.</text>
    </action>
    <action datetime="2022-05-18" state="REPORTED">
      <text>Ordered to be Reported (Amended) by the Yeas and Nays: 55 - 0.</text>
    </action>
    <action datetime="2022-06-07">
      <text>Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 117-348.</text>
    </action>
    <calendar datetime="2022-06-07" calendar="Union" number="262">
      <text>Placed on the Union Calendar, Calendar No. 262.</text>
    </calendar>
    <action datetime="2022-06-07T18:17:55-04:00">
      <text>Mr. Pallone moved to suspend the rules and pass the bill, as amended.</text>
    </action>
    <action datetime="2022-06-07T18:18:16-04:00">
      <text>Considered under suspension of the rules.</text>
      <reference ref="CR H5298-5321" label="consideration"/>
    </action>
    <action datetime="2022-06-07T18:18:18-04:00">
      <text>DEBATE - The House proceeded with forty minutes of debate on H.R. 7667.</text>
    </action>
    <action datetime="2022-06-07T18:38:20-04:00">
      <text>At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.</text>
    </action>
    <action datetime="2022-06-08T20:23:21-04:00">
      <text>Considered as unfinished business.</text>
      <reference ref="CR H5402-5403" label="consideration"/>
    </action>
    <vote how="roll" type="vote" roll="254" datetime="2022-06-08T20:31:13-04:00" where="h" result="pass" suspension="1" state="PASS_OVER:HOUSE">
      <text>On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 392 - 28 (Roll no. 254).</text>
      <reference ref="06/07/2022 CR H5298-5319" label="text"/>
    </vote>
    <action datetime="2022-06-08T20:31:14-04:00">
      <text>Motion to reconsider laid on the table Agreed to without objection.</text>
    </action>
    <action datetime="2022-06-09">
      <text>Received in the Senate.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Reporting, Markup, Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Reporting, Markup, Referral"/>
  </committees>
  <relatedbills>
    <bill session="117" type="h" number="2565" relation="unknown"/>
    <bill session="117" type="h" number="6888" relation="unknown"/>
    <bill session="117" type="h" number="6980" relation="unknown"/>
    <bill session="117" type="h" number="7006" relation="unknown"/>
    <bill session="117" type="h" number="7032" relation="unknown"/>
    <bill session="117" type="h" number="7035" relation="unknown"/>
    <bill session="117" type="h" number="7084" relation="unknown"/>
    <bill session="117" type="h" number="7649" relation="unknown"/>
    <bill session="117" type="h" number="7658" relation="unknown"/>
    <bill session="117" type="s" number="2952" relation="unknown"/>
    <bill session="117" type="s" number="3983" relation="unknown"/>
    <bill session="117" type="s" number="4152" relation="unknown"/>
    <bill session="117" type="s" number="3478" relation="unknown"/>
    <bill session="117" type="h" number="6988" relation="unknown"/>
    <bill session="117" type="s" number="4351" relation="unknown"/>
    <bill session="117" type="s" number="4302" relation="unknown"/>
    <bill session="117" type="s" number="4333" relation="unknown"/>
    <bill session="117" type="s" number="4338" relation="unknown"/>
    <bill session="117" type="s" number="4535" relation="unknown"/>
    <bill session="117" type="h" number="9297" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Advanced technology and technological innovations"/>
    <term name="Advisory bodies"/>
    <term name="Animal protection and human-animal relationships"/>
    <term name="Blood and blood diseases"/>
    <term name="Business records"/>
    <term name="Cardiovascular and respiratory health"/>
    <term name="Child health"/>
    <term name="Computer security and identity theft"/>
    <term name="Congressional oversight"/>
    <term name="Criminal investigation, prosecution, interrogation"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Emergency medical services and trauma care"/>
    <term name="Employee hiring"/>
    <term name="Evidence and witnesses"/>
    <term name="Executive agency funding and structure"/>
    <term name="Food and Drug Administration (FDA)"/>
    <term name="Genetics"/>
    <term name="Government employee pay, benefits, personnel management"/>
    <term name="Government information and archives"/>
    <term name="Government studies and investigations"/>
    <term name="Health care coverage and access"/>
    <term name="Health programs administration and funding"/>
    <term name="Health technology, devices, supplies"/>
    <term name="Industrial facilities"/>
    <term name="Infectious and parasitic diseases"/>
    <term name="Inflation and prices"/>
    <term name="Licensing and registrations"/>
    <term name="Manufacturing"/>
    <term name="Marketing and advertising"/>
    <term name="Medical research"/>
    <term name="Minority health"/>
    <term name="Musculoskeletal and skin diseases"/>
    <term name="Organ and tissue donation and transplantation"/>
    <term name="Performance measurement"/>
    <term name="Photography and imaging"/>
    <term name="Prescription drugs"/>
    <term name="Product development and innovation"/>
    <term name="Public participation and lobbying"/>
    <term name="Public-private cooperation"/>
    <term name="Radiation"/>
    <term name="Research and development"/>
    <term name="Small business"/>
    <term name="User charges and fees"/>
  </subjects>
  <amendments/>
  <summary date="2022-06-25T00:31:45Z" status="Passed House">Food and Drug Amendments of 2022

This bill reauthorizes Food and Drug Administration (FDA) user fee programs for certain drugs and devices, establishes requirements to increase diversity in clinical trials, and modifies requirements relating to the overall supply chain for drugs and devices.

Specifically, the bill reauthorizes through FY2027 the FDA user fee programs for prescription drugs, medical devices, generic drugs, and biosimilars.

The bill also requires the development of action plans and related reporting to increase the diversity of participants in clinical trials.

In addition, the bill requires the FDA to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why).

The bill also (1) establishes requirements and reauthorizes programs to support the development of specific categories of drugs and devices (e.g., pediatric drugs) and inspections of drug manufacturing facilities; and (2) establishes and revises requirements relating to the approval of drugs and devices, including requirements for postapproval studies and guidance about using real-world evidence to support drug and device applications.</summary>
  <committee-reports>
    <report>H. Rept. 117-348</report>
  </committee-reports>
</bill>
